The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

摘要: ABSTRACT Background Despite recent progress in the treatment of ovarian cancer, majority patients eventually relapse. There is little information on effectiveness chemotherapy higher lines. Patients and methods Characterization second to sixth line therapy its effects survival was carried out, based data n = 1620 from three large randomized phase III trials investigating primary therapy. Results Median progression-free (PFS) after first, second, third, fourth fifth relapse 10.2 [95% confidence interval (CI) 9.6–10.7], 6.4 (5.9–7.0), 5.6 (4.8–6.2), 4.4 (3.7–4.9) 4.1 (3.0–5.1) months, respectively. overall (OS) 17.6 (95% CI 16.4–18.6), 11.3 (10.4–12.9), 8.9 (7.8–9.9), 6.2 (5.1–7.7) 5.0 (3.8–10.4) The most frequent third platinum combination (n = 313, 24.5%) topotecan (n = 118, 23.6%), Relapse improved PFS OS at recurrence, although frequently not performed according standard care. In multivariate analysis, sensitivity optimal tumor debulking were revealed as independent prognostic factors for up Conclusion A maximum lines subsequent seems be beneficial with recurrent cancer. Optimal remain even more relapses.